We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Harnessing the Immune System Against Cancer by Targeting CD25

The shared CD25 activation mechanism on regulatory and effector T cells has been a big challenge when designing immunotherapy drugs. Cancer Research UK scientists from University College London in collaboration with Roche, have developed a new antibody that can target CD25 specifically on regulatory T cells while leaving effector T cells intact. Watch this antibody in action in this short animation.

Read the Nature paper on this area of research here.  


Advertisement